Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- After an ugly week, all we can do is look forward, Jim Cramer told his "Mad Money" TV show viewers Friday. That's why his game plan for next week's trading focuses on earnings and the upcoming Federal Reserve meeting on Tuesday and Wednesday.
Cramer said he'll be starting his week watching the rest of the world, with fresh economic data coming in from China and Europe. He said either of these reports could spark an over-sold rally on Monday. Cramer was also bullish on both Sprint (S) and T-Mobile US (TMUS) on the latest rumors a merger could be brewing.
Then, on Tuesday, Cramer said all eyes will be on the Fed, which will likely begin talking about easing its bond buying as all of the recent economic news has been very bullish. Also on the menu: Jabil Circuit (JBL), the part supplier that could tip us to how Apple (AAPL) products are selling. Cramer currently owns shares of Apple for his charitable trust, Action Alerts PLUS.
For Wednesday, it's earnings from FedEx (FDX), a stock that's rebounding along with economic growth, General Mills (GIS) a stock that's now just marking time as interest rates creep higher, and home builder Lennar (LEN), which should have decent numbers but will likely fall anyway. Cramer was bearish on Oracle (ORCL), which also reports Wednesday.
Next, on Thursday, more earnings from ConAgra (CAG), a stock Cramer said it too risky; Darden Restaurants (DRI), a stock worth buying if it gets hit; and two retail plays, Nike (NKE) and Pier 1 Imports (PIR), both Cramer faves.
Finally, on Friday, we reach the finish line with, well, Finish Line (FINL). Cramer said he'd be a buyer of this stock on Thursday ahead of its results.
Executive Decision: Tarek Sherif
For his "Executive Decision" segment, Cramer sat down with Tarek Sherif, chairman and CEO of Medidata Solutions (MDSO - Get Report), the cloud computing company for clinical development whose shares soared 193% in 2013 and over 50% since Cramer last spoke with Sherif in July.
Sherif once again explained that drug makers currently spend over $90 billion a year bringing new drugs to market, and that process is only getting more and more complicated as new regulations and safety concerns couple with more and more complex drugs. In that environment, traditional in-house software just isn't flexible enough, he said, which is why the cloud computing model makes so much sense.
Sherif said Medidata's platform allows drug makers to get drugs to market sooner with increased safety and at lower costs by increasing the productivity and efficiency of their clinical trials.